Inhaled nitric oxide by pulmonary hypertension:: Comparison preterm infants versus newborn infants

被引:0
|
作者
Schmölzer, G [1 ]
Urlesberger, B [1 ]
Reiterer, F [1 ]
Haim, M [1 ]
Kutschera, J [1 ]
Resch, B [1 ]
Müller, W [1 ]
机构
[1] Graz Univ, Klin Kinder & Jugenheilkunde Graz, Klin Abt Neonatol, A-8036 Graz, Austria
来源
KLINISCHE PADIATRIE | 2003年 / 215卷 / 05期
关键词
inhaled nitric oxide; pulmonary hypertension; term infants; preterm infants;
D O I
暂无
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Inhaled nitric oxide (iNO) is used as a vasodilator in pulmonary hypertension (PH) of the newborn infant. Patients and Methods: Retrospective analysis of patients, who were treated at our department with iNO in the period from 1994-001. Response was defined as an increase of the paO(2)/FiO(2) Ratio greater than or equal to 20% and/or a decrease of the oxygenation index (OI) greater than or equal to 20 % after 2 h (early response), and consecutively after. 24 h (late response). The patients were divided into a) primary persistent pulmonary hypertension of the newborn (PPHN), or b) pulmonary hypertension secondary to meconium aspiration syndrome (MAS), sepsis or congenital diaphragmatic hernia (CDH). Results: Between 1994 and 2001 we treated 47 patients with iNO at our neonatal intensive care unit. We included 16 (35%) preterm infants (GA 34,5 [25-37] weeks, GG 2061 [680-3410]g) (Median/Range) and 31 (65%) newborn (GA40 [38-42] weeks, GG 3510 [2550-4560]g). 18 (38%) patients suffered from primary PPHN, 29 (62%) from secondary PPHN (14 MAS [30%], 8 sepsis [17%], 4 CDH [8%]). 8 (50%) preterm and 20 (64%) term infants showed a positive NO response after 2 h, again 8 (50 %) preterm, and 20 (64%) term infants showed a positive NO response after 24h. There was neither a significant difference between term and preterm infants at 2 h, nor at 24 h. Between 2 h and 24 h 10 patients changed in their response to iNO. 5 (18 %) patients with early response showed a significant degradation after 24h, whereas 5 (26%) of the patients without early response showed a significant improvement of the oxygenation alter 24h. Alltogether 13 (72%) patients with PPHN, 8 (57%) with MAS, 2 (50%) with CDH, 4 (50%) with sepsis showed a positive iNO response after 24h. In regard to the oxygenation parameters at start of iNO-therapy, the patients with early response did not differ from the patient without response (median 01: 20,0 versus 21,8, median paO(2)/FiO(2) Ratio: 59,3 versus 55,0 mmHg at the start of the iNO therapy). Conclusion: In regard to iNO response, there was no significant difference between term and preterm infants. Due to the changing response, a positive iNO-response after 2 h had no predictive value for the further prognosis of the oxygenation situation under iNO therapy.
引用
收藏
页码:257 / 261
页数:5
相关论文
共 50 条
  • [41] Nitric oxide levels in preterm and term infants and in premature infants with bacteremia
    Marom, D
    Yuhas, Y
    Sirota, L
    Livni, G
    Ashkenazi, S
    BIOLOGY OF THE NEONATE, 2004, 86 (03): : 160 - 164
  • [42] Is inhaled nitric oxide a miraculous molecule? The analysis of nitric oxide use in newborns with persistent pulmonary hypertension of the newborn
    Srnkova, Patricia
    Brucknerova, Jana
    Brucknerova, Ingrid
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2022, 123 (03): : 153 - 159
  • [43] Oxygen therapy in preterm infants with pulmonary hypertension
    Chandrasekharan, Praveen
    Lakshminrusimha, Satyan
    SEMINARS IN FETAL & NEONATAL MEDICINE, 2020, 25 (02)
  • [44] Management of Postoperative Pulmonary Hypertension by Inhaled Nitric Oxide in a Newborn with Congenital Diaphragmatic Hernia
    Fettah, Nurdan Dinlen
    Dilli, Dilek
    Cavusoglu, Hakan
    Beken, Serdar
    Ozgur, Senem
    Zenciroglu, Aysegul
    Okumus, Nurullah
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2014, 24 (09): : 690 - 691
  • [45] Pulmonary Hypertension in Preterm Infants with Bronchopulmonary Dysplasia
    Baker, Christopher D.
    Abman, Steven H.
    Mourani, Peter M.
    PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY, 2014, 27 (01) : 8 - 16
  • [46] Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn
    Lorch, SA
    Cnaan, A
    Barnhart, K
    PEDIATRICS, 2004, 114 (02) : 417 - 426
  • [47] Inhaled nitric oxide: a more physiological treatment or persistent pulmonary arterial hypertension in the newborn
    Thebaud, B
    Mercier, JC
    ARCHIVES DE PEDIATRIE, 1997, 4 (10): : 988 - 1003
  • [48] Inhaled Nitric Oxide in Preterm Infants: An Individual-Patient Data Meta-analysis of Randomized Trials
    Askie, Lisa M.
    Ballard, Roberta A.
    Cutter, Gary R.
    Dani, Carlo
    Elbourne, Diana
    Field, David
    Hascoet, Jean-Michel
    Hibbs, Anna Maria
    Kinsella, John P.
    Mercier, Jean-Christophe
    Rich, Wade
    Schreiber, Michael D.
    Wongsiridej, Pimol
    Subhedar, Nim V.
    Van Meurs, Krisa P.
    Voysey, Merryn
    Barrington, Keith
    Ehrenkranz, Richard A.
    Finer, Neil N.
    PEDIATRICS, 2011, 128 (04) : 729 - 739
  • [49] Inhaled nitric oxide and intravenous magnesium sulphate for the treatment of persistent pulmonary hypertension of the newborn
    Boo, N. Y.
    Rohana, J.
    Yong, S. C.
    Bilkis, A. Z.
    Yong-Junina, F.
    SINGAPORE MEDICAL JOURNAL, 2010, 51 (02) : 144 - 150
  • [50] Risk factors and outcomes of early pulmonary hypertension in preterm infants
    Seth, Saad Ahmed
    Soraisham, Amuchou Singh
    Harabor, Andrei
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2018, 31 (23) : 3147 - 3152